Free shipping on all orders over $ 500
Roquinimex (LS2616; FCF89) is a quinoline-3-carboxamide with potential antineoplastic activity, which increases NK cell activity and macrophage cytotoxicity. Roquinimex at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS blood when analysed in vitro.
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Molecular Weight | 308.33 |
| Formula | C18H16N2O3 |
| CAS Number | 84088-42-6 |
| Purity | >98% |
| Solubility | DMSO ≥ 60 mg/mL |
| Storage | at -20°C |
[3] Q Liu, et al. Inflamm Res. Roquinimex inhibits dextran sodium sulfate-induced murine colitis
| Related TNF-alpha Products |
|---|
| C25-140
C25-140, a first-in-class, orally active, and fairly selective TRAF6-Ubc13 inhibitor, directly binds to TRAF6, and blocks the interaction of TRAF6 with Ubc13. C25-140 lowers TRAF6 activity, reduces NF-κB activation, and combats autoimmunity. |
| AX-024
AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. |
| 1,4-Dicaffeoylquinic acid
1,4-Dicaffeoylquinic acid (1,4-DCQA) is a phenylpropanoid from Xanthii fructus, inhibits LPS-stimulated TNF-α production. |
| UCB-9260
UCB-9260 is an orally active small molecule that inhibits tumor necrosis factor (TNF) signaling through an asymmetrical form of a stable trimer. UCB-9260 is more selective to tumor necrosis factor than other superfamily members and binds to tumor necrosis factor Kd The value is 13 nM. |
| UTL-5g
UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
